Live fluorescent RNA-based detection of pluripotency gene expression in embryonic and induced pluripotent stem cells of different species

Stem Cells

Volumn 33, Issue 2, 2015, Pages 392-402

  Lahm, Harald ^a   Doppler, Stefanie ^a   Dreßen, Martina ^a   Werner, Astrid ^a   Adamczyk, Klaudia ^a   Schrambke, Dominic ^a   Brade, Thomas ^b   Laugwitz, Karl Ludwig ^b,c   Deutsch, Marcus André ^a   Schiemann, Matthias ^a,d   Lange, Rüdiger ^a,c   Moretti, Alessandra ^b,c   Krane, Markus ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Embryonic stem cells; Fluorescent nanoparticles; Induced pluripotent stem cells; Live staining; Pluripotency

Indexed keywords

DOUBLE STRANDED DNA; GOLD NANOPARTICLE; GREEN FLUORESCENT PROTEIN; RNA; CARBOCYANINE; CYANINE DYE 3; OLIGONUCLEOTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EMBRYO; EMBRYONIC STEM CELL; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSDUCTION; GERM LAYER; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; SOMATIC CELL; SWINE; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; METABOLISM; NUCLEAR REPROGRAMMING; PIG; TRANSGENIC MOUSE;

IPS; MURINAE; SUS;

ANIMALS; CARBOCYANINES; CELLULAR REPROGRAMMING; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES; SWINE;

EID: 84921666526     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1872     Document Type: Article

References (44)

1. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
2. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
3. Liao J, Cui C, Chen S, et al. Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 2009; 4: 11-15.
4. Liu H, Zhu F, Yong J, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 2008; 3: 587-590.
5. Luo J, Suhr ST, Chang EA, et al. Generation of leukemia inhibitory factor and basic fibroblast growth factor-dependent induced pluripotent stem cells from canine adult somatic cells. Stem Cells Dev 2011; 20: 1669-1678.
6. Bao L, He L, Chen J, et al. Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. Cell Res 2011; 21: 600-608.
7. Esteban MA, Xu J, Yang J, et al. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem 2009; 284: 17634-17640.
8. Carvajal-Vergera X, Sevilla A, D'Souza SI, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465: 808-812.
9. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. New Engl J Med 2010; 363: 1397-1409.
10. Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012; 4: 130ra47.
11. Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mod Cell Neurosci 2013; 56: 355-364.
12. Gorba T, Conti L,. Neural stem cells as tools for drug discovery: Novel platforms and approaches. Expert Opin Drug Discov 2013; 8: 1083-1094.
13. Shinozawa T, Imahashi K, Sawada H, et al. Determination of appropriate stage of human-induced pluripotent stem cell-derived cardiomyocytes for drug screening and pharmacological evaluation in vitro. J Biomol Screen 2012; 17: 1192-1203.
14. Olmer R, Lange A, Selzer S, et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C Methods 2012; 18: 772-784.
15. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012; 126: S29-S37.
16. Marti M, Mulero L, Pardo C, et al. Characterization of pluripotent stem cells. Nat Protoc 2013; 8: 223-253.
17. Wada N, Wang B, Lin NH, et al. Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. J Periodontal Res 2011; 46: 438-447.
18. Chan EM, Ratanasirintrawoot S, Park I-H, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 2009; 5: 1033-1037.
19. Baker M,. Reprogramming: Faithful reporters. Nat Methods 2011; 9: 231-234.
20. Singh U, Quintanilla RH, Grecian S, et al. Novel alkaline phosphatase substrate for identification of pluripotent stem cells. Stem Cell Rev Rep 2012; 8: 1021-1029.
21. Kang N-Y, Yun S-W, Ha H-H, et al. Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1. Nat Protoc 2011; 6: 1044-1052.
22. Desbordes SC, Studer L,. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat Protoc 2013; 8: 111-130.
23. Bock C, Kiskins E, Verstappen G, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011; 144: 439-452.
24. Patel SN, Wu Y, Bao Y, et al. TaqMan® OpenArray® high-throughput transcriptional analysis of human embryonic and induced pluripotent stem cells. Methods Mol Biol 2013; 997: 191-201.
25. Valamehr B, Robinson M, Abujarour R, et al. platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Rep 2014; 2: 336-381.
26. Wu SM, Fujiwara Y, Cibulsky SM, et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell 2006; 127: 1137-1150.
27. Gu M, Nguyen PK, Lee AS, et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res 2012; 111: 882-893.
28. Sommer CA, Stadtfeld M, Murphy GJ, et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009; 27: 543-549.
29. Clark AT, Rodriguez RT, Bodnar MS, et al. Human STELLAR, NANOG and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells 2004; 22: 169-179.
30. Ban KB, Wile B, Kim S, et al. Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons targeting cardiomyocyte-specific mRNA. Circulation 2013; 128: 1897-1909.
31. Reubinoff BE, Pera MF, Fong CY, et al. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 2000; 18: 399-404.
32. Levine AJ, Brivanlou AH,. GDF3 at the crossroads of TGF-β signaling. Cell Cycle 2006; 5; 1069-1073.
33. Radzisheuskaya A, Chia GLE, dos Santos RL, et al. A defined Oct4 level governs cell state transitions of pluripotency entry and differentiation into all embryonic lineages. Nat Cell Biol 2013; 15: 579-590.
34. Kalmar T, Lim C, Hayward P, et al. Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol 2009; 7: e1000149.
35. Laugwitz K-L, Moretti A, Lam J, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005; 433: 647-653.
36. Moretti A, Caron L, Nakano A, et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006; 127: 1151-1165.
37. Bu L, Jiang X, Martin-Puig S, et al. Human ISL1 progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009; 460: 113-117.
38. Mehta A, Sequiera GL, Ramachandra CJA, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res 2014; 102: 497-506.
39. Seftor EA, Seftor REB, Weldon DS, et al. Melanoma tumor cell heterogeneity: A molecular approach to study subpopulations expressing the embryonic morphogen Nodal. Semin Oncol 2014; 41: 259-266.
40. Khare S, Ratsimandresy RA, de Almeida L, et al. The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA virus. Nat Immunol 2014; 15: 343-353.
41. Rao M,. iPSC crowdsourcing: A model for obtaining large panels of stem cell lines for screening. Cell Stem Cell 2013; 13: 389-391.
42. Li M, Suzuki K, Kim NY, et al. A cut above the rest: Targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 2014; 289: 4594-4599.
43. Soldner F, Laganière J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011; 146: 318-331.
44. Zou J, Sweeney CL, Chou B-K, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117: 5561-5572.